Business, Health Care

Merck announces Week 96 data from Phase 2b study evaluating Islatravir in combination with Doravirine in adults with HIV-1 infection

Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified Company Also Presenting Phase 1/1b Results for MK-8507, a New Investigational Once-Weekly Oral HIV Agent; Company Advances MK-8507 to Phase 2 KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known

News Now!, Politics

Trump can’t block tax subpoena: Circuit court

A federal appeals court in New York ruled Wednesday President Donald Trump cannot block enforcement of a subpoena for his tax returns issued by the Manhattan District Attorney’s office. A three-judge panel of the 2nd U.S. Circuit Court of Appeals said President

Business, Health Care

Opdivo (nivolumab) plus chemotherapy show statistically significant improvement in pathologic complete response as neoadjuvant treatment of resectable non-small cell lung cancer in phase 3 CheckMate-816 trial

[contact-form][contact-field label=”Name” type=”name” required=”true” /][contact-field label=”Email” type=”email” required=”true” /][contact-field label=”Website” type=”url” /][contact-field label=”Message” type=”textarea” /][/contact-form] CheckMate –816 met a primary endpoint of improved pathologic complete response in patients who received Opdivo plus chemotherapy before surgery Positive results mark the first time an